ライフサイエンスコーパス: highly aggressive

1 ural crest origin, and half of the cases are highly aggressive.

2 E) cancers range from relatively indolent to highly aggressive.

3 In support of this concept, metastasis of highly aggressive 4T1 breast cancer cells in mice can be

4 ival in animals injected subcutaneously with highly aggressive 4T1 cells revealed 5 of 5 deaths of PB

5 cing a chimaeric MLL oncogene give rise to a highly aggressive acute leukaemia associated with poor c

6 the brain for hundreds of genes between the highly aggressive Africanized honey bee compared with Eu

7 Highly aggressive Africanized honeybees (AHB) invaded Pu

8 ity of this new class of inhibitors to treat highly aggressive AML by targeting LICs.

9 ancer aggression and metastasis and HCC is a highly aggressive and angiogenic cancer.

10 and overexpress the cellular c-MYC gene are highly aggressive and carry a very poor prognosis.

11 he most lethal gynecologic malignancy; it is highly aggressive and causes almost 125,000 deaths yearl

12 ights a novel therapeutic approach to target highly aggressive and chemoresistant MYC-activated cance

13 Renal cancers are highly aggressive and clinically challenging, but a tran

14 81ab1 as a potential therapeutic target in 2 highly aggressive and difficult to treat KRAS-mutated ca

15 oteolytic activity; metastatic melanoma is a highly aggressive and drug-resistant form of skin cancer

16 in humans and mice leads to an early onset, highly aggressive and fatal autoimmune disease affecting

17 Cutaneous malignant melanoma is a highly aggressive and frequently chemoresistant cancer,

18 a subset of small-cell lung cancer (SCLC), a highly aggressive and frequently lethal human tumour wit

19 Malignant pleural mesothelioma (MPM) is a highly aggressive and generally incurable cancer.

20 Glioblastoma (GBM) is a highly aggressive and heterogeneous form of brain cancer

21 h it is known that these RESTless tumors are highly aggressive and include all tumor subtypes, the un

22 Glioblastoma (GBM; grade 4 glioma) is a highly aggressive and incurable tumor.

23 But in the setting of melanoma, a highly aggressive and invariably fatal malignancy in its

24 at Id-1 mRNA was constitutively expressed in highly aggressive and invasive human breast cancer cells

25 ade B-cell malignancy that transforms into a highly aggressive and lethal disease at a rate of 2% per

26 Small cell lung cancer (SCLC) is a highly aggressive and lethal neoplasm.

27 CIC-DUX4 sarcoma is a highly aggressive and lethal subtype of small round cell

28 -rich networks in situ, has been observed in highly aggressive and malignant melanoma.

29 marate hydratase-deficient renal cancers are highly aggressive and metastasize even when small, leadi

30 oped advanced lung adenocarcinomas that were highly aggressive and metastasized to multiple intrathor

31 In contrast, nuclear extracts from highly aggressive and metastatic cell lines do not conta

32 Triple-negative breast cancer (TNBC) is a highly aggressive and metastatic form of breast cancer t

33 ras(G12D) , culminated in the development of highly aggressive and metastatic PDAC despite de-repress

34 n hepatocellular carcinoma (HCC) fostering a highly aggressive and metastatic phenotype.

35 pheral primitive neuroectodermal tumors, are highly aggressive and mostly affect children and adolesc

36 n lesions called leiomyomas (ULM), and rare, highly aggressive and pleomorphic tumors named leiomyosa

37 ) with respect to expression and function in highly aggressive and poorly aggressive human cutaneous

38 ised, these donor cells initiate a much more highly aggressive and rapidly fatal disease.

39 Pancreatic cancer is highly aggressive and refractory to existing therapies.

40 Pancreatic cancer is highly aggressive and refractory to most existing therap

41 overexpressing lung cancers, which are often highly aggressive and resistant to chemotherapy.

42 igher risk of bearing breast tumors that are highly aggressive and resistant to therapies.

43 DLBCL exhibits highly aggressive and systemic progression into multiple

44 3-ITD-reconstituted animals, which died of a highly aggressive and transplantable AML within 3 to 5 m

45 ressors Tp53 or Ink4a/Arf in mice triggers a highly aggressive and transplantable precursor B-ALL.

46 with activating RAS mutations are typically highly aggressive and treatment-refractory, yet RAS muta

47 euroendocrine malignant neoplasm that can be highly aggressive and ultimately lethal.

48 evidence that YAP is silenced in a subset of highly aggressive and undifferentiated human colorectal

49 Notch4ICD tumors were highly aggressive and well vascularized, indicating a ro

50 )Trp53(d/d) tumors in 12-month-old mice were highly aggressive, and metastasized to nearby and distan

51 The disease is highly aggressive, and survival is in the range of sever

52 The maize MuDR/Mu transposable elements are highly aggressive, and their activities are held in chec

53 The loss of T reg cells leads to fatal, highly aggressive, and widespread immune-mediated lesion

54 LSF in less aggressive HCC cells resulted in highly aggressive, angiogenic, and multiorgan metastatic

55 uences on mesocortical serotonin circuits in highly aggressive animals via feedback to autoreceptors

56 agenesis and cooperate with c-Myc to produce highly aggressive B cell lymphomas.

57 2 prolonged survival of mice challenged with highly aggressive B-ALL.

58 Mantle cell lymphoma (MCL) is a highly aggressive B-cell lymphoma resistant to conventio

59 eolytic activity of MALT1 is associated with highly aggressive B-cell lymphomas.

60 Primary effusion lymphoma (PEL) is a highly aggressive B-cell malignancy that is closely asso

61 Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), w

62 f FOXC2 is significantly correlated with the highly aggressive basal-like subtype of human breast can

63 cribed as particularly effective against the highly-aggressive basal/triple-negative subtype of breas

64 st cancer cells and shore hypomethylation in highly aggressive, basal-like cells.

65 were consistently overexpressed in the more highly aggressive BC cells.

66 fourth of ES cases and define a subset with highly aggressive behavior and poor chemoresponse.

67 ignant melanoma (CMM), already known for its highly aggressive behavior and resistance to conventiona

68 As these tumors exhibited highly aggressive behavior, the possibility of exploitin

69 es of cancer cell lines from two E2F1-driven highly aggressive bladder and breast tumors, and use net

70 n kinase (MAPK) pathway that is deficient in highly aggressive BLBCs treated with chemotherapy, leadi

71 ell metastatic propensities, being lowest in highly aggressive BMBC cell variants compared with eithe

72 Glioblastoma multiforme (GBM) is a highly aggressive brain cancer that is characterized by

73 Glioblastoma is a highly aggressive brain tumor.

74 Malignant gliomas are highly aggressive brain tumors that display many of thes

75 y potentially improve the treatment of these highly aggressive brain tumors.

76 Glioblastoma are highly aggressive brain tumours that are associated with

77 e, suboptimal dose administration of DNTs in highly aggressive breast cancer and melanoma mouse model

78 We further show that, in the highly aggressive breast cancer cell line MDAMB231, wher

79 melanocyte-specific proteins as did another highly aggressive breast cancer cell line.

80 methylation in several cancers, whereas some highly aggressive breast cancer cells exhibit genomic lo

81 tatic breast cancer cell lines as well as in highly aggressive breast cancer specimens.

82 Claudin-low tumors are a highly aggressive breast cancer subtype with no targeted

83 minogen activation receptor (uPAR, PLAUR) in highly aggressive breast cancer subtypes and cell lines.

84 11 signatures sharing a phenotype related to highly aggressive breast cancer.

85 ith Her2/neu proto-oncogene amplification in highly aggressive breast cancers and induced by Her2/neu

86 gn lesions and could also define a subset of highly aggressive breast cancers.

87 nterfering RNA directed to ERRalpha into the highly aggressive breast carcinoma MDA-MB-231 cell line

88 Highly aggressive Burkitt lymphoma (BL) with rapidly pro

89 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer type characterized by rapid met

90 NUT midline carcinoma (NMC) is a rare but highly aggressive cancer typically caused by the translo

91 Hepatocellular carcinoma (HCC) is a highly aggressive cancer with no currently available eff

92 Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few tre

93 e management of patients suffering from this highly aggressive cancer.

94 r clear cell renal cell carcinoma (ccRCC), a highly aggressive cancer.

95 ial molecular target for the therapy of this highly aggressive cancer.

96 issue-level program supporting the growth of highly aggressive cancers and early-stage metastases.

97 hotothermal transducers for the treatment of highly aggressive cancers and large tumors where the pen

98 Mutation of p53 is indicative of highly aggressive cancers and poor prognosis.

99 it exhibits moderate to poor effects against highly aggressive cancers including triple-negative and

100 sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characteriz

101 ver 50% of all cancers and are indicative of highly aggressive cancers that are hard to treat.

102 ent of the SAGA complex, is overexpressed in highly aggressive cancers, but the normal functions of t

103 ally advantageous for treating many types of highly aggressive cancers.

104 s therapeutic lead compounds for a number of highly aggressive cancers.

105 10 of 45 cases of poorly differentiated and highly aggressive carcinoma with metaplastic morphology.

106 aggressiveness, possibly suggesting that in highly aggressive cell lines, key signaling enzymes are

107 vels to avoid the expansion of resistant and highly aggressive cells.

108 The highly aggressive character of melanoma makes it an exce

109 n in adult T-cell leukemia/lymphoma (ATL), a highly aggressive chemotherapy-resistant malignancy.

110 SMARCB1 gene in malignant rhabdoid tumors, a highly aggressive childhood cancer.

111 BCR-ABL1-Abl1(-/-) cells generated highly aggressive chronic myeloid leukemia (CML)-blast p

112 tics, and the mechanisms responsible for the highly aggressive clinical picture of hepatocellular car

113 udy is proof of concept that a PDOX model of highly aggressive colon-cancer metastasis can identify e

114 the molecular mechanism underlying a case of highly aggressive colorectal cancer and illustrates the

115 Merkel cell carcinoma (MCC) is a rare but highly aggressive cutaneous neuroendocrine tumor.

116 Glioblastoma (GB) is a highly aggressive, difficult to treat brain tumour.

117 Ovarian cancer is a highly aggressive disease and novel treatments are requi

118 2-positive (HER2(+)) breast cancer (BC) is a highly aggressive disease commonly treated with chemothe

119 c adenocarcinoma presents as a spectrum of a highly aggressive disease in patients.

120 Melanoma is a highly aggressive disease that is difficult to treat owi

121 Esophageal adenocarcinoma (EAC) is a highly aggressive disease with poor long-term survival.

122 pite major advances in the treatment of this highly aggressive disease with potent inhibitors of the

123 apies to improve the dismal outcomes in this highly aggressive disease.

124 d with triple-negative tumors that represent highly aggressive disease.

125 loping new treatments for patients with this highly aggressive disease.

126 ding triple-negative breast cancer (TNBC), a highly aggressive disease.

127 gains and structural rearrangements to form highly aggressive disease.

128 f alphavbeta3 and TAMs to not only eradicate highly aggressive drug-resistant human lung and pancreas

129 trast, BJ3Z cells do not alter the growth of highly aggressive ER-negative MDA-MB-231 human breast ca

130 Furthermore, these formerly highly aggressive flies lose all competitive advantage o

131 After a defeat, however, these highly aggressive flies lose their second fights against

132 Inflammatory breast cancer (IBC) is a highly aggressive form of breast cancer that displays pr

133 Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits ex

134 e-negative breast cancer (TNBC) represents a highly aggressive form of breast cancer with limited tre

135 nocytes that facilitates development of this highly aggressive form of breast cancer.

136 ancer vaccines or immunotherapy against this highly aggressive form of breast cancer.

137 tions identify a phenotypically distinct and highly aggressive form of MCL with poor or no response t

138 s a Gram-negative bacterium that can cause a highly aggressive form of neonatal meningitis, which oft

139 vary, hypercalcemic type (SCCOHT) is a rare, highly aggressive form of ovarian cancer primarily diagn

140 MCPyV is associated with a highly aggressive form of skin cancer in humans.

141 Melanoma is the most serious, highly aggressive form of skin cancer with recent dramat

142 Merkel cell carcinoma is a highly aggressive form of skin cancer.

143 Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new ther

144 Metaplastic breast carcinoma (MBC) is a highly aggressive form of triple-negative cancer (TNBC),

145 (NUT) midline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell

146 ated with chemoresistance and progression to highly aggressive forms of CLL, and the advent of new th

147 le xenograft models and in an autochthonous, highly aggressive genetically engineered mouse model of

148 expression of PKCalpha mRNA was detected in highly aggressive glioblastoma multiforme as compared wi

149 ssion of EGFRvIII variants as a signature of highly aggressive gliomas and to identify patients that

150 whether it functions as an oncogene in this highly aggressive group of bone and soft tissue tumors.

151 onomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell

152 ificantly abrogated growth and metastasis of highly aggressive HCC cells in nude mice.

153 HCC with partial penetrance and exhibit more highly aggressive HCC induced by chemical carcinogenesis

154 asis, whereas Alb/AEG-1/c-Myc mice developed highly aggressive HCC with frank metastasis to the lungs

155 Triple-negative breast cancer (TNBC) is a highly aggressive, heterogeneous disease with poor progn

156 In summary, EPOCH had broad efficacy against highly aggressive HIV-NHLs, whereas vorinostat had no be

157 Glioblastoma multiforme is the most common highly aggressive human brain cancer, and receptor tyros

158 therapeutic opportunities for TNBC and other highly aggressive human cancers of epithelial origin.

159 ved in promoting the growth of a subclass of highly aggressive human GBMs that lack EGF receptor ampl

160 All compounds were tested in the highly aggressive human melanoma cell lines A2058 and A3

161 PFE (10-100 microg/ml; 48 h) treatment of highly aggressive human prostate cancer PC3 cells result

162 MV isolated from highly aggressive human TNBC cells impart metastatic pot

163 ited in Trp53(-/-)Ssbp2(-/-) mice to develop highly aggressive, immature thymic lymphomas.

164 PA to pre-existing p53-deficient tumors in a highly aggressive, immunocompetent mouse model of lung a

165 They can be highly aggressive in subsequent interactions, supporting

166 transmitted through organ transplants and is highly aggressive in transplant recipients.

167 t(15;19)(q13, p13.1) is characterized by its highly aggressive, invariably lethal clinical course.

168 Mesothelioma is highly aggressive; its sarcomatoid variants have worse p

169 Triple-negative breast cancers (TNBC) are highly aggressive, lack FDA-approved targeted therapies,

170 g sulfolane electrolyte can also support the highly aggressive LiNi(0.8) Mn(0.1) Co(0.1) O(2) (NMC811

171 topic xenograft (PDOX) nude mouse model of a highly aggressive liver metastasis of colon cancer.

172 oids are not early progenitor lesions of the highly aggressive lung neuroendocrine tumours but arise

173 R inhibitors, which results in recurrence of highly aggressive lung tumors.

174 xposure to an environmental PAH can induce a highly aggressive lymphoma in mice and raises the possib

175 ular features with Burkitt lymphoma (BL) are highly aggressive lymphomas with poor clinical outcome.

176 The invasive ability of the highly aggressive Mahlavu cell was attenuated by pre-miR

177 Uterine carcinosarcomas (UCSs) are highly aggressive malignancies associated with poor prog

178 arcinomas (CCCs) are a histological group of highly aggressive malignancies commonly originating in t

179 primitive neuroectodermal tumors (PNET), are highly aggressive malignancies predominantly affecting c

180 ancreatic and bile duct carcinomas represent highly aggressive malignancies that evolve from secretin

181 Early detection of the highly aggressive malignancy cholangiocarcinoma (CCA) re

182 Metastatic melanoma is a highly aggressive malignancy that has traditionally been

183 es of triple-negative breast cancer (TNBC)-a highly aggressive malignancy with a dismal posttreatment

184 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with a dismal survival rate

185 or and HER2 (also called ERBB2 or NEU)--is a highly aggressive malignancy with limited treatment opti

186 Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes associat

187 Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor survival rates, w

188 Glioblastoma multiforme (GBM) is a highly aggressive malignant brain tumor with fatal outco

189 ntracranial glial neoplasms ranging from the highly aggressive malignant glioblastoma multiforme (GBM

190 Pancreatic cancer is highly aggressive, malignant, and notoriously difficult

191 agonistic differences, with bHRs acting in a highly aggressive manner when facing homecage intrusion.

192 dactyl clubs of the stomatopods, a group of highly aggressive marine crustaceans.

193 ms identifies Burkitt lymphoma/leukemia as a highly aggressive mature B-cell neoplasm consisting of e

194 gen peroxide (H(2)O(2)), particularly in the highly aggressive MDA-MB-231 breast cancer cells.

195 ly affected by ectopic expression of REST in highly aggressive MDA-MB-231 cells.

196 -interference-mediated knockdown of SATB1 in highly aggressive (MDA-MB-231) cancer cells altered the

197 We have discovered that in WM1158, a highly aggressive melanoma cell line, down-regulation of

198 l (VE)-cadherin was exclusively expressed by highly aggressive melanoma cells and was undetectable in

199 rs that appear to be aberrantly expressed in highly aggressive melanoma cells, causing melanoma cell

200 The procoagulant function of TF on highly aggressive melanoma is shown to be regulated by T

201 Furthermore, growth of highly aggressive melanoma isograft tumors was suppresse

202 mimicry (VM) describes the unique ability of highly aggressive melanoma tumor cells to express endoth

203 Highly aggressive, metastatic melanoma is notoriously re

204 ve breast cancer, or basal breast cancer, is highly aggressive, metastatic, and difficult to treat.

205 ial lining of the thoracic cavity leads to a highly aggressive MM that recapitulates the histological

206 nificant extension in lifespan, even in this highly aggressive model of disease.

207 in relatively unchanged for less common, but highly aggressive, mold infections such as mucormycosis.

208 EGFR overexpression is a characteristic of highly aggressive molecular subtypes of breast cancer wi

209 ATSM in a mouse breast tumor model using the highly aggressive mouse mammary carcinoma cell line EMT-

210 l breach in immunological tolerance, causing highly aggressive multi-organ autoimmune pathology.

211 ers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rat

212 The highly aggressive muscle cancer alveolar rhabdomyosarcom

213 nd demonstrate that mutant females develop a highly aggressive myeloproliferative neoplasm and myelod

214 deadliest form of skin cancer because of its highly aggressive nature and the lack of effective treat

215 Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive neoplasm characterized by a marked fib

216 Melanomas are highly aggressive neoplasms resistant to most convention

217 Malignant melanoma is a highly aggressive neoplastic disease whose incidence is

218 ng RNA reduced the tumorigenic properties of highly aggressive neuroblastoma cells.

219 The majority of Merkel cell carcinoma, a highly aggressive neuroendocrine cancer of the skin, is

220 80% of all Merkel cell carcinomas (MCCs), a highly aggressive neuroendocrine carcinoma of the skin.

221 Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with profou

222 Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with steadi

223 sociated with Merkel cell carcinoma (MCC), a highly aggressive neuroendocrine skin cancer.

224 ntribute to the oncogenic progression in the highly aggressive NMC.

225 p significantly repressed tumour growth in a highly aggressive NSCLC circulating tumour cell (CTC) pa

226 combination for pre-clinical development in highly aggressive NSCLC.

227 translocation t(15;19) that accounts for the highly aggressive NUT midline carcinoma (NMC).

228 Conjunctival melanoma (CM) is a highly aggressive ocular cancer for which treatment opti

229 in vivo outcomes of drug combinations in the highly aggressive orthotopic 4T1 murine breast cancer mo

230 In vivo activity in a highly aggressive orthotopic C6 glioma model demonstrate

231 mplified gene in human cancer, including the highly aggressive ovarian serous carcinoma.

232 provide solvent-free product, and the use of highly aggressive oxidants, such as iodine monochloride.

233 ncreased in various human cancers, including highly aggressive pancreatic cancers, but the mechanisms

234 Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive pediatric brainstem tumor characterize

235 Malignant rhabdoid tumors (MRT) are highly aggressive pediatric cancers that respond poorly

236 utic target and treatment approach for these highly aggressive pediatric cancers.

237 (H3K27M) gain-of-function mutations occur in highly aggressive pediatric gliomas.

238 Rhabdoid tumors (RTs) are rare, highly aggressive pediatric malignancies with poor progn

239 outcomes for this biologically distinct and highly aggressive pediatric malignancy.

240 bserved in malignant rhabdoid tumor (MRT), a highly aggressive pediatric neoplasm.

241 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.

242 cation as a central genetic determinant of a highly aggressive phenotype that directs the worst clini

243 erved that these cells were converted into a highly aggressive phenotype, as primary tumors that form

244 f the central nervous system (CNS-PNETs) are highly aggressive, poorly differentiated embryonal tumor

245 ce and increases survival in glioblastoma, a highly aggressive primary brain tumor.

246 Glioblastomas are highly aggressive primary brain tumours, which display h

247 ells as a test model system because of their highly aggressive proliferative nature.

248 We found that ZEB1 is expressed in highly aggressive prostate cancer cells and that its exp

249 of early malignant changes and subsequently highly aggressive prostate tumors at a younger age, comp

250 ar double-step processes, each of which uses highly aggressive reagents, and each generates substanti

251 agnostic target for tumor monitoring of this highly aggressive sarcoma.

252 eral nerve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of

253 ith that of podoplanin during progression to highly aggressive SCCs in a mouse skin model of carcinog

254 Merkel cell carcinoma (MCC) is a rare and highly aggressive skin cancer associated with the Merkel

255 Merkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer for which immune modulatio

256 sheath tumors (MPNSTs) represent a group of highly aggressive soft-tissue sarcomas that may occur sp

257 noculated directly into primary 4T1 tumor, a highly aggressive, spontaneously metastasizing mammary c

258 Triple-negative breast cancer (TNBC) is a highly aggressive subcategory of breast cancer and curre

259 A highly aggressive subset of pancreatic ductal adenocarci

260 Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer that remains am

261 Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited tr

262 Triple-negative breast cancer (TNBC) is a highly aggressive subtype that is untreatable with hormo

263 eral nerve sheath tumors (MPNST), a class of highly aggressive, therapeutically resistant, and common

264 MPNSTs are highly aggressive, therapeutically resistant, and typica

265 analysis comparing low aggressive TM40D and highly aggressive TM40D-MB mouse mammary carcinoma cells

266 herapeutic strategy to treat drug-resistant, highly aggressive TNBC tumors.

267 as a novel BRD4-NUT target that supports the highly aggressive transforming activity of t(15;19) carc

268 time of mice bearing large (>1000mm(3)) and highly aggressive triple negative breast tumors is doubl

269 Efforts to improve the clinical outcome of highly aggressive triple-negative breast cancer (TNBC) h

270 added diagnostic benefit in identifying the highly aggressive triple-negative cancer phenotype with

271 e Notch3 receptor has been correlated to the highly aggressive "triple negative" human breast cancer.

272 E Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive tumor of lymphoid origin which is occa

273 of cancer, including medulloblastoma (MB), a highly aggressive tumor of the cerebellum.

274 Cutaneous melanoma is a highly aggressive tumor that is relatively resistant to

275 Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor prognosis.

276 Pancreatic cancer is a highly aggressive tumor, mostly resistant to the standar

277 d led to the eradication of well-established highly aggressive tumors and the development of long-ter

278 2.2, 28.6) but was elevated for moderate and highly aggressive tumors as well (odds ratios = 6.6 and

279 d many breast cancer cell lines derived from highly aggressive tumors contain high levels of activate

280 e cell lines with altered Ron protein formed highly aggressive tumors in the lungs.

281 hed tumor stem cell population, resulting in highly aggressive tumors in vivo.

282 The RB1 tumor suppressor gene is mutated in highly aggressive tumors including small-cell lung cance

283 iffuse intrinsic pontine gliomas (DIPGs) are highly aggressive tumors of childhood that are almost un

284 Malignant gliomas are highly aggressive tumors of the central nervous system t

285 Malignant mesotheliomas are highly aggressive tumors usually caused by exposure to a

286 Induction of UVB-derived mutations yields highly aggressive tumors with decreased anti-tumor activ

287 Melanoma is a highly aggressive tumour that can metastasize very early

288 Pancreatic cancer, a highly aggressive tumour type with uniformly poor progno

289 ransplantation of transformed iNPCs leads to highly aggressive tumours containing undifferentiated st

290 general associated with a worse outcome, but highly aggressive tumours with 11q13-14 amplification ha

291 K fusion occurs in a subset of patients with highly aggressive types of thyroid cancer and provide in

292 ast, miR-375 is strikingly down-regulated in highly aggressive, undifferentiated MCC cell lines.

293 tumor control and survival benefits in both highly aggressive unilateral and bilateral B16-F10 murin

294 of neuroendocrine prostate cancer (NEPC), a highly aggressive variant of CRPC.

295 Hepatocellular carcinoma (HCC) is a highly aggressive vascular cancer characterized by diver

296 onverted nontumorigenic human HCC cells into highly aggressive vascular tumors, and inhibition of AEG

297 y analysis from our laboratory comparing the highly aggressive versus the poorly aggressive melanoma

298 Additionally, TTP(min) can help identify highly aggressive WHO III astrocytoma tumors and may hel

299 These tumors are highly aggressive with a median survival of less than 2

300 Basal-like breast cancers (BLBC) are highly aggressive, yet selective therapies targeting the